These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. The present status of psychotropic drugs. Dally P Practitioner; 1970 Sep; 205(227):307-12. PubMed ID: 5484906 [No Abstract] [Full Text] [Related]
24. Atypical depression. A valid clinical entity? Stewart JW; McGrath PJ; Rabkin JG; Quitkin FM Psychiatr Clin North Am; 1993 Sep; 16(3):479-95. PubMed ID: 8415233 [TBL] [Abstract][Full Text] [Related]
25. Treatment of resistant depression. Kelly D Pharmakopsychiatr Neuropsychopharmakol; 1974 Jul; 7(4):199-204. PubMed ID: 4614275 [No Abstract] [Full Text] [Related]
26. [Some current aspects of antidepressive therapy]. Predescu V; Vianu I Neurol Psihiatr Neurochir; 1967; 12(6):485-94. PubMed ID: 5593224 [No Abstract] [Full Text] [Related]
27. Not all monoamine oxidase inhibitors are created equal. Stewart JT J Am Geriatr Soc; 2007 Nov; 55(11):1890. PubMed ID: 17979910 [No Abstract] [Full Text] [Related]
28. A choice--drugs or electroshock for depression. Koutsky CD Dis Nerv Syst; 1966 Dec; 27(12):806-7. PubMed ID: 5954741 [No Abstract] [Full Text] [Related]
29. [Deficiencies and needs in the use of tricyclic antidepressive agents]. Deniker P; Ginestet D Therapie; 1973; 28(2):235-48. PubMed ID: 4766357 [No Abstract] [Full Text] [Related]
30. What is the bottom line for dietary guidelines when taking monoamine oxidase inhibitors? Marcason W J Am Diet Assoc; 2005 Jan; 105(1):163. PubMed ID: 15635366 [No Abstract] [Full Text] [Related]
31. [Psychotropic drugs in internal medicine. I. Antidepressants]. de la Fuente JR Rev Invest Clin; 1983; 35(3):247-56. PubMed ID: 6415779 [No Abstract] [Full Text] [Related]
32. [Is the thyrotropic hormone an antidepressive agent?]. Deniker P; Ginestet D; Loo H; Zarifian E Ann Med Interne (Paris); 1976 Jan; 127(1):51-4. PubMed ID: 827224 [No Abstract] [Full Text] [Related]
33. Psychopharmacological treatment of disorders of senescence. Fann WE; Wheless JC; Richman BW N C Med J; 1974 Nov; 35(11):672-7. PubMed ID: 4530160 [No Abstract] [Full Text] [Related]
35. [Management of endogenous depressions using psychopharmacologic agents]. Kielholz P; Pöldinger W Dtsch Med Wochenschr; 1968 Apr; 93(14):701-4. PubMed ID: 5660916 [No Abstract] [Full Text] [Related]
36. [Response to psychotropic drugs in depressive syndromes. Clinico-statistical contribution]. Bini A; Liberati F; Pompili A; Sinibaldi L Riv Neurol; 1968 Dec; 39(6):605-14. PubMed ID: 5748175 [No Abstract] [Full Text] [Related]
37. [Pharmaclogical modification of depressive symptoms]. Fragoso Mendes J; Lopes Da Silva F Actas Luso Esp Neurol Psiquiatr; 1965 Mar; 24(1):21-7. PubMed ID: 5828671 [No Abstract] [Full Text] [Related]
38. MAO inhibition and antidepressant activity. Feldstein A; Hoagland H; Rivera Oktem M; Freeman H Int J Neuropsychiatry; 1965 Aug; 1(4):384-7. PubMed ID: 5324597 [No Abstract] [Full Text] [Related]
39. Results of the STAR*D study: implications for clinicians and drug developers. Preskorn SH J Psychiatr Pract; 2009 Jan; 15(1):45-9. PubMed ID: 19182564 [No Abstract] [Full Text] [Related]
40. [Mechanism of action of psychopharmaca]. Roos BE Nord Med; 1967 Dec; 78(50):1651-2. PubMed ID: 6073280 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]